Fourier Transform Infrared (FTIR) spectroscopy to monitor the cellular impact of newly synthesized platinum derivatives

International Journal of Oncology

Volumn 37, Issue 3, 2010, Pages 679-686

  Berger, Gilles ^a   Gasper, Régis ^a   Lamoral Theys, Delphine ^a   Wellner, Anja ^b   Gelbcke, Michel ^a   Gust, Ronald ^b,c   Nève, Jean ^a   Kiss, Robert ^a   Goormaghtigh, Erik ^a   Dufrasne, François ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Fourier transform infrared spectroscopy; Platinum derivatives

Indexed keywords

CRYSTAL VIOLET; NITROBLUE TETRAZOLIUM; PLATINUM DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CALORIMETRY; CELL ACTIVITY; CELL ASSAY; CHEMICAL ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; PRIORITY JOURNAL; TUMOR GROWTH; VALIDITY;

ANIMALS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MICE; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 77956507237     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000717     Document Type: Article

References (51)

1. Kelland LR: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584, 2007.
2. Galanski M: Recent developments in the field of anticancer platinum complexes. Recent Patents Anti-Cancer Drug Discov 1: 285-295, 2006.
3. Shah N and Dizon DS: New-generation platinum agents for solid tumors. Future Oncol 5: 33-42, 2009.
4. McKeage MJ: Comparative adverse effect profiles of platinum drugs. Drug Saf 13: 228-244, 1995.
5. Giaccone G: Clinical perspectives on platinum resistance. Drugs 59: S9-S17, 2000.
6. O'Dwyer PJ, Stevenson JP and Johnson SW: Clinical pharmacokinetics and administration of established platinum drugs. Drugs 59: S19-S27, 2000.
7. Galanski M, Jakupec MA and Keppler BK: Oxaliplatin and derivatives as anticancer drugs-novel design strategies. In: Metal Compounds in Anticancer Chemotherapy. Perez JM, Fuertes MA and Alonso C (eds). Research Singpost, Kerala, pp155-185, 2005.
8. Stordal B, Pavlakis N and Davey R: Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review. Cancer Treat Rev 33: 347-357, 2007. (Pubitemid 46760527)
9. Culy CR, Clemett D and Wiseman LR: Oxaliplatin. Drugs 60: 895-924, 2000.
10. Hall MD and Hambley TW: Platinum (IV) antitumour compounds; their bioorganic chemistry. Coord Chem Rev 232: 49-67, 2002.
11. Coluccia M and Natile G: Trans-platinum complexes in cancer therapy. Anti-Cancer Agents Med Chem 7: 111-123, 2007.
12. Farrell NP: Polynuclear charged platinum compounds as a new class of anticancer agents: toward a new paradigm. In: Platinum-Based Drugs in Cancer Therapy. Kelland LR and Farrell NP (eds). Humana Press, Totowa, New Jersey, pp321-338, 2000.
13. Van Zutphen S and Reedijk J: Targeting platinum anti-tumour drugs: Overview of strategies employed to reduce systemic toxicity. Coord Chem Rev 249: 2845-2853, 2005.
14. Jung YW and Lippard SJ: Direct cellular responses to platinum-induced DNA damage. Chem Rev 107: 1387-1407, 2007. (Pubitemid 46864967)
15. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
16. Gust R, Gelbcke M, Angermaier B, Bachmann H, Krauser R and Schöhenberger H: The stereoselectivity of antitumor active [1,2-diamino-1-phenylpropane]dichloroplatinum(II) complexes. Inorg Chim Acta 264: 145-160, 1997.
17. Dufrasne F, Gelbcke M, Schnurr B and Gust R: Synthesis and antitumor activity of enantiomerically pure [1,2-diamino-1-(4-fluorophenyl)propane] dichloroplatinum(II) complexes. Arch Pharm 335: 229-239, 2002.
18. Dullin A, Dufrasne F, Gelbcke M and Gust R: Enantiomerically pure [1,2-diamino-1-(4-fluorophenyl)butane]platinum(II) complexes: Synthesis and antitumor activity against MCF-7 and MDA-MB 231 breast cancer and LnCaP/FGC prostate cancer cell lines. Arch Pharm 337: 654-667, 2004.
19. Dullin A, Dufrasne F, Gelbcke M and Gust R: Synthesis and cytotoxicity of enantiomerically pure [1,2-diamino-1-(4-fluorophenyl)-3-methylbutane] platinum(II) complexes. ChemMedChem 1: 644-653, 2006. (Pubitemid 44105791)
20. Gasper R, Dewelle J, Kiss R, Mijatovic T and Goormaghtigh E: IR spectroscopy as a new tool for evidencing antitumor drug signatures. Biochim Biophys Acta - Biomembranes 1788: 1263-1270, 2009.
21. Matier WL, Owens DA, Comer WT, Deitchman D, Ferguson HC, Seidehamel RJ and Young JR: Antihypertensive agents. synthesis and biological properties of 2-amino-4-aryl-2-imidazolines. J Med Chem 16: 901-908, 1973.
22. Gust R, Lubczyk V, Schmidt K and Shihada U: Synthesis, conformational studies, and investigations on the estrogen receptor binding of [R/S-1-(2,6-dichloro-4hydroxyphenyl)-ethylenediamine]platinum (II) complexes. Arch Pharm 334: 93-100, 2001.
23. Van Quaquebeke E, Simon G, Andre A, Dewelle J, Yazidi ME, Bruyneel F, Tuti J, Nacoulma O, Guissou P, Decaestecker C, Braekman JC, Kiss R and Darro F: Identification of a novel cardenolide (2″-oxovorusharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro anti-tumor activities and high in vivo tolerance: Structure-activity relationship analyses. J Med Chem 48: 849-856, 2005.
24. Ozalp-Yaman S, de Hoog P, Amadei G, Pitié M, Gamez P, Dewelle J, Mijatovic T, Meunier B, Kiss R and Reedijk J: Platinated copper (3-clip-phen) complexes as effective DNA-cleaving and cytotoxic agents. Chemistry-Eur J 14: 3418-3426, 2008.
25. Lamoral-Theys D, Andolfi A, Van Goietsenoven G, Cimmino A, Le Calvé B, Wauthoz N, Mégalizzi V, Gras T, Bruyère C, Dubois J, Mathieu V, Kornienko A, Kiss R and Evidente A: Lycorine, the main phenanthridine Amaryllidaceae alkaloid, exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: An investigation of structure-activity relationship and mechanistic insight. J Med Chem 52: 6244-6256, 2009.
26. Bernhardt G, Reile H, Birnböck H, Spruss T and Schöneneberger H: Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity. J Cancer Res Clin Oncol 118: 35-43, 1992.
27. Reile H, Birnböck H, Bernhardt G, Spruss T and Schönenberger H: Computerized determination of growth kinetic curves and doubling times from cells in microcultures. Anal Biochem 187: 262-267, 1990. (Pubitemid 20183465)
28. Gaigneaux A, Decaestecker C, Camby I, Mijatovic T, Kiss R, Ruyschaert JM and Goormaghtigh E: The infrared spectrum of human glioma cells is related to their in vitro and in vivo behavior. Exp Cell Res 297: 294-301, 2004.
29. +-ATPase) to combat glioblastoma cells. Neurosurgery 62: 211-222, 2008.
30. Ingrassia L, Lefranc F, Dewelle J, Pottier L, Mathieu V, Spiegl-Kreinecker S, Sauvage S, El Yazidi M, Dehoux M, Berger W, Van Quaquebeke E and Kiss R: Structure-activity-relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae Isocarbostyril alkaloid) as potential anti-cancer agents. J Med Chem 52: 1100-1114, 2009.
31. Mijatovic T, Mathieu V, Gaussin JF, De Neve N, Ribaucour F, Van Quaquebeke E, Dumont P, Darro F and Kiss R: Cardenolide-induced lysosomal membrane permeabilization contributes therapeutic benefits in experimental human non-small-cell-lung cancers. Neoplasia 8: 402-412, 2006.
32. Mathieu V, Pirker C, Martin de Lassalle E, Vernier M, Mijatovic T, DeNeve N, Gaussin JF, Dehoux M, Lefranc F, Berger W and Kiss R: The sodium pump alpha-1 subunit: a disease progression-related target for metastatic melanoma treatment. J Cell Mol Med 9: 3960-3972, 2010.
33. Bruyère C, Mijatovic T, De Nève N, Gaussin JF, Gras T, Nindfa P, Dehoux M, Saussez S and Kiss R: Combining proapoptotic or pro-autophagic chemotherapies with chemokine inhibition in experimental esophageal cancers. Proc Am Assoc Cancer Res, Abst 4135, 2009.
34. Dumont P, Ingrassia L, Rouzeau S, Ribaucour F, Thomas S, Roland I, Darro F, Lefranc F and Kiss R: The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the Death Receptor and/or the mitochondrial pathways in cancer cells but not in normal fibroblasts. Neoplasia 9: 766-776, 2007.
35. Branle F, Lefranc F, Camby I, Jeuken J, Geurts-Moespot A, Sprenger S, Sweep F, Kiss R and Salmon I: Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p/19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer 95: 641-655, 2002.
36. Bruggisser R, von Daeniken K, Jundt G, Schaffer W and Tullberg-Reinert H: Interference of plant extracts, phytoestrogens and antioxydants with the MTT tetrazolium assay. Planta Med 68: 445-448, 2002. (Pubitemid 34606689)
37. Naumann D: Infrared spectroscopy in microbiology. In: Encyclopedia of Analytical Chemistry. Meyers RA (ed). John Wiley & Sons Ltd, Chichester, pp102-131, 2000.
38. Teicher BA: Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res 14: 1610-1617, 2008.
39. Chen D, Milacic V, Frezza M and Dou QP: Metal complexes, their cellular targets and potential for cancer therapy. Curr Pharm Des 15: 777-791, 2009.
40. Zhang J, Liu D, Li Y, Sun J, Wang L and Zang A: Status of non-classical mononuclear platinum anticancer drug development. Mini Rev Med Chem 9: 1357-1366, 2009.
41. Cassidy J and Misset JL: Oxaliplatin-related side effects: characteristics and management. Semin Oncol 29: 11-20, 2002.
42. Bhargava A and Vaishampayan UN: Satraplatin: leading the new generation of oral platinum agents. Expert Opin Investig Drugs 18: 1787-1797, 2009.
43. Montana AM and Batalla C: The rational design of anticancer platinum complexes: the importance of the structure-activity relationship. Curr Med Chem 16: 2235-2260, 2009
44. Hambley TW: The influence of structure on the activity and toxicity of Pt anticancer drugs. Coord Chem Rev 166: 181-223 (1997)
45. Jamieson E and Lippard SJ: Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99: 2467-2498, 1999.
46. Pani E, Stojic L, El-Shemerly M, Jiricny J and Ferrari S: Mismatch repair status and the response of human cells to cisplatin. Cell Cycle 6: 1796-1802, 2007.
47. Beretta GL, Gatti L, Corna E, Carenini N, Zunino F and Perego P: Defining targets of modulation of human tumor cell response to cisplatin. J Inorg Biochem 102: 1406-1415, 2008.
48. Zlatanova J, Yaneva J and Leuba SH: Proteins that specifically recognize cisplatin-damaged DNA: a clue to anticancer activity of cisplatin. FASEB J 12: 791-799, 1998. (Pubitemid 28294669)
49. Vrana O and Brabec V: L-methionine inhibits reaction of DNA with anticancer cis-diamminedichloroplatinum(II). Biochemistry 41: 10994-10999, 2004.
50. Rabik C and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23, 2007.
51. Knipp M: Metallothioneins and platinum(II) anti-tumor compounds. Curr Med Chem 16: 522-537, 2009.